Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis.

Baechler SA, Factor VM, Dalla Rosa I, Ravji A, Becker D, Khiati S, Miller Jenkins LM, Lang M, Sourbier C, Michaels SA, Neckers LM, Zhang HL, Spinazzola A, Huang SN, Marquardt JU, Pommier Y.

Nat Commun. 2019 Jan 8;10(1):83. doi: 10.1038/s41467-018-07922-3.

2.

Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo.

Thakur S, Daley B, Gaskins K, Vasko VV, Boufraqech M, Patel D, Sourbier C, Reece J, Cheng SY, Kebebew E, Agarwal S, Klubo-Gwiezdzinska J.

Clin Cancer Res. 2018 Aug 15;24(16):4030-4043. doi: 10.1158/1078-0432.CCR-17-3167. Epub 2018 Apr 24.

3.

Hyperpolarized [1-13C]-Pyruvate Magnetic Resonance Spectroscopic Imaging of Prostate Cancer In Vivo Predicts Efficacy of Targeting the Warburg Effect.

Scroggins BT, Matsuo M, White AO, Saito K, Munasinghe JP, Sourbier C, Yamamoto K, Diaz V, Takakusagi Y, Ichikawa K, Mitchell JB, Krishna MC, Citrin DE.

Clin Cancer Res. 2018 Jul 1;24(13):3137-3148. doi: 10.1158/1078-0432.CCR-17-1957. Epub 2018 Mar 29.

PMID:
29599412
4.

Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers.

Sourbier C, Liao PJ, Ricketts CJ, Wei D, Yang Y, Baranes SM, Gibbs BK, Ohanjanian L, Spencer Krane L, Scroggins BT, Keith Killian J, Wei MH, Kijima T, Meltzer PS, Citrin DE, Neckers L, Vocke CD, Marston Linehan W.

Oncotarget. 2018 Jan 10;9(12):10723-10733. doi: 10.18632/oncotarget.24112. eCollection 2018 Feb 13.

5.

Uncoupling tumor-stroma interactions in breast cancer patients.

Sourbier C, Neckers L.

Semin Oncol. 2017 Jun;44(3):235-236. doi: 10.1053/j.seminoncol.2017.10.008. Epub 2017 Oct 18. No abstract available.

PMID:
29248136
6.

Detecting the Potential Pharmacological Synergy of Drug Combination by Viability Assays In Vitro.

Gibbs BK, Sourbier C.

Methods Mol Biol. 2018;1709:129-137. doi: 10.1007/978-1-4939-7477-1_10.

PMID:
29177656
7.

Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M.

Li QQ, Hsu I, Sanford T, Railkar R, Balaji N, Sourbier C, Vocke C, Balaji KC, Agarwal PK.

Cell Mol Life Sci. 2018 Mar;75(5):939-963. doi: 10.1007/s00018-017-2681-z. Epub 2017 Oct 25.

PMID:
29071385
8.

Plasma HSP90α and liver cancer: a potential biomarker?

Sourbier C.

EBioMedicine. 2017 Nov;25:7-8. doi: 10.1016/j.ebiom.2017.10.012. Epub 2017 Oct 10. No abstract available.

9.

Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276).

Yang Y, Vocke CD, Ricketts CJ, Wei D, Padilla-Nash HM, Lang M, Sourbier C, Killian JK, Boyle SL, Worrell R, Meltzer PS, Ried T, Merino MJ, Metwalli AR, Linehan WM.

Genes Chromosomes Cancer. 2017 Oct;56(10):719-729. doi: 10.1002/gcc.22476. Epub 2017 Jul 24.

10.

Discovering Targets of Non-enzymatic Acylation by Thioester Reactivity Profiling.

Kulkarni RA, Worth AJ, Zengeya TT, Shrimp JH, Garlick JM, Roberts AM, Montgomery DC, Sourbier C, Gibbs BK, Mesaros C, Tsai YC, Das S, Chan KC, Zhou M, Andresson T, Weissman AM, Linehan WM, Blair IA, Snyder NW, Meier JL.

Cell Chem Biol. 2017 Feb 16;24(2):231-242. doi: 10.1016/j.chembiol.2017.01.002. Epub 2017 Feb 2.

11.

Co-opting a Bioorthogonal Reaction for Oncometabolite Detection.

Zengeya TT, Garlick JM, Kulkarni RA, Miley M, Roberts AM, Yang Y, Crooks DR, Sourbier C, Linehan WM, Meier JL.

J Am Chem Soc. 2016 Dec 14;138(49):15813-15816. Epub 2016 Nov 30.

12.

Synthesis of a stable and orally bioavailable englerin analogue.

Fash DM, Peer CJ, Li Z, Talisman IJ, Hayavi S, Sulzmaier FJ, Ramos JW, Sourbier C, Neckers L, Figg WD, Beutler JA, Chain WJ.

Bioorg Med Chem Lett. 2016 Jun 1;26(11):2641-4. doi: 10.1016/j.bmcl.2016.04.016. Epub 2016 Apr 8.

13.

SnapShot: Renal Cell Carcinoma.

Ricketts CJ, Crooks DR, Sourbier C, Schmidt LS, Srinivasan R, Linehan WM.

Cancer Cell. 2016 Apr 11;29(4):610-610.e1. doi: 10.1016/j.ccell.2016.03.021.

14.

SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery.

Saxena N, Maio N, Crooks DR, Ricketts CJ, Yang Y, Wei MH, Fan TW, Lane AN, Sourbier C, Singh A, Killian JK, Meltzer PS, Vocke CD, Rouault TA, Linehan WM.

J Natl Cancer Inst. 2016 Jan;108(1). doi: 10.1093/jnci/djv287.

15.

Lack of mitochondrial topoisomerase I (TOP1mt) impairs liver regeneration.

Khiati S, Baechler SA, Factor VM, Zhang H, Huang SY, Dalla Rosa I, Sourbier C, Neckers L, Thorgeirsson SS, Pommier Y.

Proc Natl Acad Sci U S A. 2015 Sep 8;112(36):11282-7. doi: 10.1073/pnas.1511016112. Epub 2015 Aug 24.

16.

Tonantzitlolone cytotoxicity toward renal cancer cells is PKCθ- and HSF1-dependent.

Sourbier C, Scroggins BT, Mannes PZ, Liao PJ, Siems K, Wolf D, Beutler JA, Linehan WM, Neckers L.

Oncotarget. 2015 Oct 6;6(30):29963-74. doi: 10.18632/oncotarget.4676.

17.

Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma.

Lu Y, Xu W, Ji J, Feng D, Sourbier C, Yang Y, Qu J, Zeng Z, Wang C, Chang X, Chen Y, Mishra A, Xu M, Lee MJ, Lee S, Trepel J, Linehan WM, Wang X, Yang Y, Neckers L.

Hepatology. 2015 Oct;62(4):1122-31. doi: 10.1002/hep.27923. Epub 2015 Jul 3.

18.

Metabolism and oxidative stress response pathways in kidney cancer: a tale of chance and necessity.

Sourbier C, Srinivasan R, Linehan WM.

Am Soc Clin Oncol Educ Book. 2015:220-5. doi: 10.14694/EdBook_AM.2015.35.220. Review.

19.

New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease.

Srinivasan R, Ricketts CJ, Sourbier C, Linehan WM.

Clin Cancer Res. 2015 Jan 1;21(1):10-7. doi: 10.1158/1078-0432.CCR-13-2993.

20.

Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer.

Sourbier C, Ricketts CJ, Matsumoto S, Crooks DR, Liao PJ, Mannes PZ, Yang Y, Wei MH, Srivastava G, Ghosh S, Chen V, Vocke CD, Merino M, Srinivasan R, Krishna MC, Mitchell JB, Pendergast AM, Rouault TA, Neckers L, Linehan WM.

Cancer Cell. 2014 Dec 8;26(6):840-850. doi: 10.1016/j.ccell.2014.10.005.

21.

Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity.

Khiati S, Dalla Rosa I, Sourbier C, Ma X, Rao VA, Neckers LM, Zhang H, Pommier Y.

Clin Cancer Res. 2014 Sep 15;20(18):4873-81. doi: 10.1158/1078-0432.CCR-13-3373. Epub 2014 Apr 8.

22.

The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models.

Miyajima N, Tsutsumi S, Sourbier C, Beebe K, Mollapour M, Rivas C, Yoshida S, Trepel JB, Huang Y, Tatokoro M, Shinohara N, Nonomura K, Neckers L.

Cancer Res. 2013 Dec 1;73(23):7022-33. doi: 10.1158/0008-5472.CAN-13-1156. Epub 2013 Oct 11.

23.

Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma.

Yang Y, Lane AN, Ricketts CJ, Sourbier C, Wei MH, Shuch B, Pike L, Wu M, Rouault TA, Boros LG, Fan TW, Linehan WM.

PLoS One. 2013 Aug 15;8(8):e72179. doi: 10.1371/journal.pone.0072179. eCollection 2013.

24.

Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis.

Yoshida S, Tsutsumi S, Muhlebach G, Sourbier C, Lee MJ, Lee S, Vartholomaiou E, Tatokoro M, Beebe K, Miyajima N, Mohney RP, Chen Y, Hasumi H, Xu W, Fukushima H, Nakamura K, Koga F, Kihara K, Trepel J, Picard D, Neckers L.

Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):E1604-12. doi: 10.1073/pnas.1220659110. Epub 2013 Apr 5.

25.

Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma.

Giubellino A, Sourbier C, Lee MJ, Scroggins B, Bullova P, Landau M, Ying W, Neckers L, Trepel JB, Pacak K.

PLoS One. 2013;8(2):e56083. doi: 10.1371/journal.pone.0056083. Epub 2013 Feb 14.

26.

Englerin A stimulates PKCθ to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality.

Sourbier C, Scroggins BT, Ratnayake R, Prince TL, Lee S, Lee MJ, Nagy PL, Lee YH, Trepel JB, Beutler JA, Linehan WM, Neckers L.

Cancer Cell. 2013 Feb 11;23(2):228-37. doi: 10.1016/j.ccr.2012.12.007. Epub 2013 Jan 23.

27.

Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.

Sourbier C, Srivastava G, Ghosh MC, Ghosh S, Yang Y, Gupta G, Degraff W, Krishna MC, Mitchell JB, Rouault TA, Linehan WM.

Oncotarget. 2012 Nov;3(11):1472-82.

28.

Mitochondrial topoisomerase I is critical for mitochondrial integrity and cellular energy metabolism.

Douarre C, Sourbier C, Dalla Rosa I, Brata Das B, Redon CE, Zhang H, Neckers L, Pommier Y.

PLoS One. 2012;7(7):e41094. doi: 10.1371/journal.pone.0041094. Epub 2012 Jul 20.

29.

A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer.

Yang Y, Valera V, Sourbier C, Vocke CD, Wei M, Pike L, Huang Y, Merino MA, Bratslavsky G, Wu M, Ricketts CJ, Linehan WM.

Cancer Genet. 2012 Jul-Aug;205(7-8):377-90. doi: 10.1016/j.cancergen.2012.05.001.

30.

Ovarian cancer: emerging molecular-targeted therapies.

Sourbier C.

Biologics. 2012;6:147-54. doi: 10.2147/BTT.S24155. Epub 2012 Jun 20.

31.

Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging.

Giubellino A, Woldemichael GM, Sourbier C, Lizak MJ, Powers JF, Tischler AS, Pacak K.

Cancer Lett. 2012 Mar;316(1):46-52. doi: 10.1016/j.canlet.2011.10.019. Epub 2011 Oct 20.

32.

The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.

Tong WH, Sourbier C, Kovtunovych G, Jeong SY, Vira M, Ghosh M, Romero VV, Sougrat R, Vaulont S, Viollet B, Kim YS, Lee S, Trepel J, Srinivasan R, Bratslavsky G, Yang Y, Linehan WM, Rouault TA.

Cancer Cell. 2011 Sep 13;20(3):315-27. doi: 10.1016/j.ccr.2011.07.018.

33.

Met and the microenvironment: new insights for ovarian cancer metastasis.

Sourbier C.

Cell Adh Migr. 2011 May-Jun;5(3):209-10. Epub 2011 May 1.

34.

Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma.

Sourbier C, Valera-Romero V, Giubellino A, Yang Y, Sudarshan S, Neckers L, Linehan WM.

Cell Cycle. 2010 Oct 15;9(20):4183-9. Epub 2010 Oct 27.

35.

Role of the RNA-binding protein HuR in human renal cell carcinoma.

Danilin S, Sourbier C, Thomas L, Lindner V, Rothhut S, Dormoy V, Helwig JJ, Jacqmin D, Lang H, Massfelder T.

Carcinogenesis. 2010 Jun;31(6):1018-26. doi: 10.1093/carcin/bgq052. Epub 2010 Mar 10.

PMID:
20219773
36.

UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.

Yang Y, Valera VA, Padilla-Nash HM, Sourbier C, Vocke CD, Vira MA, Abu-Asab MS, Bratslavsky G, Tsokos M, Merino MJ, Pinto PA, Srinivasan R, Ried T, Neckers L, Linehan WM.

Cancer Genet Cytogenet. 2010 Jan 1;196(1):45-55. doi: 10.1016/j.cancergencyto.2009.08.018.

37.

Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species.

Sudarshan S, Sourbier C, Kong HS, Block K, Valera Romero VA, Yang Y, Galindo C, Mollapour M, Scroggins B, Goode N, Lee MJ, Gourlay CW, Trepel J, Linehan WM, Neckers L.

Mol Cell Biol. 2009 Aug;29(15):4080-90. doi: 10.1128/MCB.00483-09. Epub 2009 May 26.

38.

von Hippel-Lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR.

Danilin S, Sourbier C, Thomas L, Rothhut S, Lindner V, Helwig JJ, Jacqmin D, Lang H, Massfelder T.

Carcinogenesis. 2009 Mar;30(3):387-96. doi: 10.1093/carcin/bgn275. Epub 2008 Dec 4.

PMID:
19056930
39.

Targeting the nuclear factor-kappaB rescue pathway has promising future in human renal cell carcinoma therapy.

Sourbier C, Danilin S, Lindner V, Steger J, Rothhut S, Meyer N, Jacqmin D, Helwig JJ, Lang H, Massfelder T.

Cancer Res. 2007 Dec 15;67(24):11668-76.

40.

Parathyroid hormone-related protein induces cell survival in human renal cell carcinoma through the PI3K Akt pathway: evidence for a critical role for integrin-linked kinase and nuclear factor kappa B.

Agouni A, Sourbier C, Danilin S, Rothhut S, Lindner V, Jacqmin D, Helwig JJ, Lang H, Massfelder T.

Carcinogenesis. 2007 Sep;28(9):1893-901. Epub 2007 Apr 29.

PMID:
17468516
41.

The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy.

Sourbier C, Lindner V, Lang H, Agouni A, Schordan E, Danilin S, Rothhut S, Jacqmin D, Helwig JJ, Massfelder T.

Cancer Res. 2006 May 15;66(10):5130-42.

42.

Parathyroid hormone-related protein in human renal cell carcinoma.

Sourbier C, Massfelder T.

Cancer Lett. 2006 Aug 28;240(2):170-82. Epub 2005 Oct 11. Review.

PMID:
16223565
43.

Antitumor effect of parathyroid hormone-related protein neutralizing antibody in human renal cell carcinoma in vitro and in vivo.

Talon I, Lindner V, Sourbier C, Schordan E, Rothhut S, Barthelmebs M, Lang H, Helwig JJ, Massfelder T.

Carcinogenesis. 2006 Jan;27(1):73-83. Epub 2005 Aug 4.

PMID:
16081513

Supplemental Content

Loading ...
Support Center